SCHEMBL6912376

SCHEMBL6912376

NC(=O)c1ncn([C@@H]2O[C@H](CI)[C@@H](OC(=O)c3ccccc3)[C@H]2OC(=O)c2ccccc2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ ADORA1 P30542 2/20 0.48
▸ ALDH1A1 P00352 1/20 0.48
▸ GLA P06280 1/20 0.48
▸ EIF4E P06730 1/20 0.48
▸ CYP3A4 P08684 1/20 0.48
▸ TOP1 P11387 1/20 0.48
▸ TSHR P16473 1/20 0.48
▸ THPO P40225 1/20 0.48
▸ PMP22 Q01453 1/20 0.48
▸ CA1 P00915 3/20 0.43
▸ CA2 P00918 3/20 0.43
▸ CA9 Q16790 3/20 0.43
▸ MEN1 O00255 1/20 0.42
▸ USP2 O75604 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ P2RX3 P56373 1/20 0.40
▸ P2RX4 Q99571 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6912924 0.91 LMNA (0.57) LMNASMN1; SMN2ADORA1ALDH1A1GLA
SCHEMBL6912407 0.90 LMNA (0.47) LMNASMN1; SMN2ADORA1ALDH1A1GLA
SCHEMBL12300734 0.90 LMNA (0.48) LMNASMN1; SMN2ADORA1ALDH1A1GLA
SCHEMBL12300349 0.88 LMNA (0.47) LMNASMN1; SMN2ADORA1ALDH1A1GLA
SCHEMBL12300344 0.86 LMNA (0.45) LMNASMN1; SMN2ADORA1ALDH1A1GLA
SCHEMBL12300346 0.84 LMNA (0.43) LMNASMN1; SMN2ADORA1ALDH1A1GLA
SCHEMBL12154681 0.84 LMNA (0.43) LMNASMN1; SMN2ADORA1ALDH1A1GLA
SCHEMBL12150424 0.84 LMNA (0.47) LMNASMN1; SMN2ADORA1ALDH1A1GLA
SCHEMBL12150476 0.84 LMNA (0.54) LMNASMN1; SMN2ADORA1ALDH1A1GLA
SCHEMBL6912115 0.83 LMNA (0.42) LMNASMN1; SMN2ADORA1ALDH1A1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040023901-A1 Nucleoside 5'-monophosphate mimics and their prodrugs BIOTA HOLDINGS LIMITED (AU) 2004-02-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040023901-A1 Nucleoside 5'-monophosphate mimics and their prodrugs MTAP, ENTPD5, PNP LMNA 4394/4885SMN1; SMN2 2624/4885ADORA1 190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback